Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 196-208

  Begum, Aynun N ^a,d   Jones, Mychica R ^a,d   Lim, Giselle P ^a,d   Morihara, Takashi ^f   Kim, Peter ^a,d   Heath, Dennis D ^e   Rock, Cheryl L ^e   Pruitt, Mila A ^e   Yang, Fusheng ^a,d   Hudspeth, Beverly ^a,d   Hu, Shuxin ^a,d   Faull, Kym F ^c   Teter, Bruce ^a,d   Cole, Greg M ^a,b,d   Frautschy, Sally A ^a,b,d,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Veteran's Greater Los Angeles Healthcare System   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CARBONYL DERIVATIVE; CURCUMIN; DRUG METABOLITE; INTERLEUKIN 1BETA; ISOPROSTANE DERIVATIVE; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; TETRAHYDROCURCUMIN;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DIET; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; ENCEPHALITIS; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 45749089694     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137455     Document Type: Article

References (40)

1. Aggarwal BB, Sundaram C, Malani N, and Ichikawa H (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1-75.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NE, Eikelenboom P, Emmerling M, Fiebich BL, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
3. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28:110-113.
4. Borsello T and Forloni G (2007) JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 13:1875-1886.
5. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, and Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85:1394-1401.
6. Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9:161-168.
7. Chan MM, Huang HI, Fenton MR, and Fong D (1998) In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55:1955-1962.
8. Chen YR and Tan TH (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17:173-178.
9. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
10. Frautschy SA, Hu W, Miller SA, Kim P, Harris-White ME, and Cole GM (2001) Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging 22:993-1005.
11. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, and Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095-1104.
12. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, et al. (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4:1502-1506.
13. Heath DD, Pruitt MA, Brenner DE, and Rock CL (2003) Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 783:287-295.
14. Heath DD, Pruitt MA, Brenner DE, Begum AN, Frautschy SA, and Rock CL (2005) Tetrahydrocurcumin in plasma and urine: quantitation by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 824:206-212.
15. Hsu HY and Wen MH (2002) Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem 277:22131-22139.
16. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, et al. (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61:1058-1064.
17. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, and Gescher AJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11:105-111.
18. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, et al. (1996) Strategy and planning for chemopreventive drug development: clinical development plan: curcumin. J Cell Biochem Suppl 26:72-85.
19. Kim H, Park BS, Lee KG, Choi CY, Jang SS, Kim YH, and Lee SE (2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 53:8537-8541.
20. Kitani K, Yokozawa T, and Osawa T (2004) Interventions in aging and age-associated pathologies by means of nutritional approaches. Ann N Y Acad Sci 1019:424-426.
21. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, and Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10.
22. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, and Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370-8377.
23. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
24. Liu A, Lou H, Zhao L, and Fan P (2006) Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40:720-727.
25. Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, and Neckers L (2006) Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2:169-174.
26. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ 2nd, Morrow JD, and Montine TJ (2004) Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128:117-124.
27. Okada K, Wangpoengtrakul C, Tanaka T, Toyokuni S, Uchida K, and Osawa T (2001) Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr 131:2090-2095.
28. Ono K, Hirohata M, and Yamada M (2005) Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun 336:444-449.
29. Pan MH, Huang TM, and Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27:486-494.
30. Pan MH, Lin-Shiau SY, and Lin JK (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappa B in macrophages. Biochem Pharmacol 60:1665-1676.
31. Pendurthi UR, Williams JT, and Rao LV (1997) Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol 17:3406-3413.
32. Puig B, Gomez-Isla T, Ribe E, Cuadrado M, Torrejon-Escribano B, Dalfo E, and Ferrer I (2004) Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30:491-502.
33. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854.
34. Sugiyama Y, Kawakishi S, and Osawa T (1996) Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol 52:519-525.
35. Thiyagarajan M and Sharma SS (2004) Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 74:969-985.
36. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, and Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378.
37. Wang YY, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, and Lin JK (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867-1876.
38. Weber WM, Hunsaker LA, Gonzales AM, Heynekamp JJ, Orlando RA, Deck LM, and Vander Jagt DL (2006) TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin. Biochem Pharmacol 72:928-940.
39. Wu A, Ying Z, and Gomez-Pinilla F (2006) Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol 197:309-317.
40. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901.